Clinical study of oxymatrine in the treatment of psoriasis

Clinical study of oxymatrine in the treatment of erythrodermic psoriasis and pustular psoriasis

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100043193

Enrollment

Unknown

Registered

2021-02-08

Start date

2018-01-01

Completion date

Unknown

Last updated

2021-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Interventions

Erythrodermic psoriasis group:Oxymatrine

Generalized pustular psoriasis:Oxymatrine

Normal control group:Nil

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Erythrodermic psoriasis, Body Surface Area (BSA) score >=75%, course of psoriasis >=6 months, and at least one previous course of systemic treatment; 2. Pustular psoriasis, course of psoriasis >=6 months, and at least one previous course of systemic treatment.

Exclusion criteria

Exclusion criteria: 1. Allergy to oxymatrine; 2. Presence of severe liver and kidney damage, mental illness, hematopoietic dysfunction, or other serious organic disease; 3. For patients with pustular psoriasis or erythrodermic psoriasis, treatment with immunosuppression, high doses of glucocorticoids or retinoid in the past 8 weeks and used topical drugs in the 4 weeks; 4. Pregnancy and lactation.

Design outcomes

Primary

Measure	Time frame
Psoriasis area and severity index;	—

Countries

China

Contacts

Public ContactHuijuan Shi

General Hospital of Ningxia Medical University

shjyjm@163.com+86 0951-6743343

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026